Exciting news from SoCalBio members, SetPoint Medical.
We are excited to share that we have filed our premarket approval (PMA) application to the FDA to advance the development of SetPoint System as potentially the first-of-its-kind neuroimmune modulation device for treatment of rheumatoid arthritis (RA). We're deeply grateful to all the SetPoint employees, RESET-RA study investigators and participants who have helped us get one step closer to offering this new treatment category to RA patients. #TheSetPointAdvantage #RheumatoidArthritis #RA This communication contains information about a device not yet approved in the United States for commercial use. The Setpoint System is limited by United States law to investigational use only.